A decade of innovation and excellence

Since its unveiling at the Academy of Osseointegration Annual Meeting in 2014, the creos brand has become synonymous with quality, reliability and outstanding clinical outcomes. By 2024, with over 20 products, three in-house manufacturing sites and numerous clinical studies, the continuously expanding creos product portfolio has remained dedicated to the provision of premium regenerative solutions.

Creos xenoprotect and beyond

One of the company’s most remarkable products is creos xenoprotect, a resorbable collagen membrane. Through over 16 published clinical cases by renowned specialists in guided bone regeneration and guided tissue regeneration, including Drs Bastian Wessing and Arturo Llobell, creos xenoprotect has earned recognition for its exceptional handling properties, predictable resorption profile and reliable performance across diverse clinical situations. Its unique composition and advanced manufacturing process ensure optimal outcomes, making it the preferred choice for dentists and surgeons seeking predictable and successful regenerative procedures. This year, creos xenoprotect reached a significant milestone with the sale of its one-millionth unit, underscoring the trust and confidence that the dental community has placed in it.

With the introduction of creos xenogain and creos xenogain collagen in 2016, the regenerative portfolio expanded into other categories beyond membranes. A wide range of products followed, including premium xenogenic bone grafts, various wound dressings, sutures and membrane fixation kits. From the first creos xenoprotect to the millionth, down to every bone grafting granule, the creos portfolio has carried the Nobel Biocare legacy proudly into the future of regeneration.

Expanding horizons through strategic acquisitions

Nobel Biocare’s journey to becoming a leader in the regenerative market has been marked by strategic acquisitions that have strengthened its product portfolio and expertise in research and development, biomaterials, manufacturing, stringent quality control and customer delivery:

• Matricel, a brand renowned for its cutting-edge biomaterial solutions, particularly resorbable collagen membranes and collagen matrix, has enhanced Nobel Biocare’s capabilities.
• Osteogenics, which has a strong reputation in the field of dPTFE membranes (Cytoplast), has bolstered Nobel Biocare’s portfolio, enabling an unmatched range of regenerative solutions for diverse clinical needs.
• Mimetis, a pioneer in synthetic bone grafting substitutes, has brought valuable expertise and technology to Nobel Biocare, further solidifying its position as a leader in dental regeneration.

These acquisitions have underscored Nobel Biocare’s commitment to expanding its regenerative product offerings and maintaining its leadership in the market. By incorporating the strengths and innovations of these companies, Nobel Biocare has continued to push the boundaries of what is possible in dental regeneration.

Looking forward: The future of regenerative solutions

As Nobel Biocare celebrates the tenth anniversary of the creos brand, the company remains committed to advancing the field of dental regeneration. Ongoing investment in research and development, coupled with the integration of new technologies and materials, ensures Nobel Biocare’s continued delivery of cutting-edge solutions that set new industry standards.

Tags: